(Q43217465)

16 November 2017

title

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique (English)

1 reference

16 November 2017

0 references

1 reference

9

1 reference

16 November 2017

Leonardo Palombi

10

0 references

Cinzia Ciccacci

object named as

Cinzia Ciccacci

1

0 references

Paola Borgiani

object named as

Paola Borgiani

2

0 references

Maria Cristina Marazzi

object named as

Maria C Marazzi

5

0 references

author name string

Susanna Ceffa

3

1 reference

16 November 2017

Elisabetta Sirianni

4

1 reference

16 November 2017

Anna M Doro Altan

6

1 reference

16 November 2017

Giovanna Paturzo

7

1 reference

16 November 2017

Placido Bramanti

8

1 reference

16 November 2017

publication date

1 January 2010

1 reference

16 November 2017

1 reference

16 November 2017

volume

11

1 reference

16 November 2017

issue

1

1 reference

16 November 2017

page(s)

23-31

1 reference

Pharmacogenetics of HIV therapy

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.142

21 January 2018

Identifiers

DOI

10.2217/PGS.09.142

1 reference

16 November 2017

1 reference